綠葉製藥(02186.HK):博安生物獲戰投1.21億元
格隆匯9月13日丨綠葉製藥(02186.HK)公吿,於2021年9月13日,公司、博安生物、原博安股東及投資者(即山東省新動能、Advantech及煙台文森)訂立認購協議,內容有關投資博安生物,注資總額為人民幣1.21億元。B2系列認購事項的估值基準與公司於2021年8月26日公佈的B1系列認購事項相同。完成B2系列認購事項須待若干條件獲達成後方可作實。
據悉,山東省新動能於2018年成立,註冊資本為人民幣200億元。其業務包括基金投資及管理。山東省新動能為山東省財金投資集團有限公司的全資附屬公司。山東省財政廳間接擁有山東省新動能的90%股權。山東省新動能另外10%股權由山東省社保基金理事會間接擁有。
博安生物為集團附屬公司,是一間全面綜合性生物製藥公司。其專門從事治療用抗體開發、製造及商業化,專注於腫瘤、自體免疫、疼痛及內分泌疾玻博安生物的抗體發現活動 圍繞三個平台展開,即全人抗體轉基因小鼠及噬菌體展示技術、雙特異性T細胞銜接系統技術以及抗體偶聯技術平台。博安生物已開發出10多個擁有國際知識產權保護的創新抗體和8個生物類似藥。
B2系列認購事項的所得款項將用作博安生物主營業務的補充營運資金。B2系列認購事項的資金將增強博安生物抵禦風險及保持市場競爭力的能力,促進博安生物的長期穩定發展。此外,進一步引進戰略投資者預期將為博安生物的發展與博安生物搶佔行業領先地位的能力帶來協同作用。鑑於博安生物的業務發展、資金需求及未來資本市場規劃,董事認為B2系列認購事項符合公司及其股東的整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.